Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Jerry Spivak • 26 Aug 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Interferon

Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, shares some insights into the challenges of treating and managing essential thrombocythemia (ET), and further discusses the biology behind ET and polycythemia vera (PV). Prof. Spivak also shares some thoughts on how to approach the treatment of these diseases. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Jerry Spivak

Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 24 Nov 2022
Polycythemia vera: disease outcomes, unmet needs and therapeutic strategies
Jerry Spivak • 10 Nov 2022
6:04
The need to improve diagnostic criteria in PV and other challenges in the field
Jerry Spivak • 26 Aug 2022
2:04
The importance of patient perspectives during treatment journeys
Jerry Spivak • 26 Aug 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals